82 results
8-K
EX-99.1
VRNA
Verona Pharma Plc
9 May 24
Verona Pharma Reports First Quarter 2024 Financial Results and Provides Corporate Update
7:22am
bronchodilator and non-steroidal anti-inflammatory benefits in one compound, the potential of ensifentrine to change the treatment paradigm for COPD patients … , consultants, principal investigators, third-party service providers and licensees; our inability to realize the anticipated benefits under licenses granted
8-K
VRNA
Verona Pharma Plc
9 May 24
Verona Pharma Announces $650 Million Strategic Financing with Oaktree and OMERS
7:18am
to be the first therapy for the treatment of respiratory diseases to combine bronchodilator and non-steroidal anti-inflammatory benefits in one compound … investigators, third-party service providers and licensees; our inability to realize the anticipated benefits under licenses granted by us to third parties
8-K
EX-99.1
3d28mruk08govz5sp
9 May 24
Verona Pharma Announces $650 Million Strategic Financing with Oaktree and OMERS
7:18am
144
rcyxsslgci ws
12 Mar 24
Notice of proposed sale of securities
7:45pm
PRE 14A
rfkp 45bsmx50ex
8 Mar 24
Preliminary proxy
4:18pm
8-K
EX-99.1
c6anh8
29 Feb 24
Verona Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
6:08am
8-K
EX-99.1
5ada53cp5jtn0jbmhme
2 Jan 24
Strengthens financial flexibility to support the Company’s continued growth
6:02am
8-K
EX-10.1
m7gu5hb t2
2 Jan 24
Strengthens financial flexibility to support the Company’s continued growth
6:02am
8-K
EX-99.1
gx4iyu s6li
2 Nov 23
Verona Pharma Reports Third Quarter 2023 Financial Results and Provides Corporate Update
6:24am
8-K
EX-99.1
krisv
3 Aug 23
Verona Pharma Reports Second Quarter 2023 Financial Results and Provides Corporate Update
6:11am